Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 …
Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …
(MRD) status after each induction course to evaluate the extent of its predictive value for …
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation …
M Balsat, A Renneville, X Thomas… - Journal of Clinical …, 2017 - ascopubs.org
Purpose This study assessed the prognostic impact of postinduction NPM1-mutated (NPM1
m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute …
m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute …
[HTML][HTML] Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high …
M Hubmann, T Köhnke, E Hoster, S Schneider… - …, 2014 - ncbi.nlm.nih.gov
Monitoring minimal residual disease is an important way to identify patients with acute
myeloid leukemia at high risk of relapse. In this study we investigated the prognostic …
myeloid leukemia at high risk of relapse. In this study we investigated the prognostic …
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
Acute myeloid leukemia (AML) with NPM1 gene mutations is currently recognized as a
distinct entity, due to its unique biological and clinical features. We summarize here the …
distinct entity, due to its unique biological and clinical features. We summarize here the …
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
J Krönke, RF Schlenk, KO Jensen… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To evaluate the prognostic value of minimal residual disease (MRD) in patients
with acute myeloid leukemia (AML) with NPM1 mutation (NPM1 mut). Patients and Method …
with acute myeloid leukemia (AML) with NPM1 mutation (NPM1 mut). Patients and Method …
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
N Shayegi, M Kramer, M Bornhäuser… - Blood, The Journal …, 2013 - ashpublications.org
Mutations of the NPM1 gene (NPM1 mut) are among the most common genetic alterations in
acute myeloid leukemia and are suitable for minimal residual disease detection. We …
acute myeloid leukemia and are suitable for minimal residual disease detection. We …
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients
M Bill, J Grimm, M Jentzsch, L Kloss, K Goldmann… - Annals of …, 2018 - Springer
Allogeneic hematopoietic stem cell transplantation is an established consolidation therapy
for patients with acute myeloid leukemia. However, relapse after transplantation remains a …
for patients with acute myeloid leukemia. However, relapse after transplantation remains a …
Assessment of minimal residual disease in standard-risk AML
A Ivey, RK Hills, MA Simpson… - … England Journal of …, 2016 - Mass Medical Soc
Background Despite the molecular heterogeneity of standard-risk acute myeloid leukemia
(AML), treatment decisions are based on a limited number of molecular genetic markers and …
(AML), treatment decisions are based on a limited number of molecular genetic markers and …
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post …
M Pratcorona, S Brunet, J Nomdedéu… - Blood, The Journal …, 2013 - ashpublications.org
Risk associated to FLT3 internal tandem duplication (FLT3-ITD) in patients with acute
myeloid leukemia (AML) may depend on mutational burden and its interaction with other …
myeloid leukemia (AML) may depend on mutational burden and its interaction with other …
Prognostic Significance of NPM1 Mutations in the Absence of FLT3–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK …
F Ostronoff, M Othus, M Lazenby, E Estey… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations
without FLT3–internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD–negative …
without FLT3–internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD–negative …
相关搜索
- standard risk partial response
- standard risk outcomes in patients
- partial response outcomes in patients
- standard risk npm1 mutations
- partial response npm1 mutations
- npm1 mutations outcomes in patients
- mutant npm1 residual disease
- high risk response assessment
- survival in aml residual disease
- survival in aml mutant npm1
- induction therapy response assessment
- absolute quantification leukemia patients
- induction therapy high risk
- droplet pcr leukemia patients
- favorable outcome npm1 mutation
- relapse and survival residual disease